title: Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib.
authors.affiliation: Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA. Electronic address: brett.king@yale.edu.
authors.forename: Brett
authors.initials: B
authors.lastname: King
authors.affiliation: Department of Medicine, Section of Hematology, Yale School of Medicine, New Haven, Connecticut, USA.
authors.forename: Alfred Ian
authors.initials: AI
authors.lastname: Lee
authors.affiliation: Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
authors.forename: Jaehyuk
authors.initials: J
authors.lastname: Choi
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000150:complications / Q000188:drug therapy*; D000075242:Janus Kinase Inhibitors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009570:Nitriles; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D011758:Pyrroles / Q000009:adverse effects / Q000627:therapeutic use*; D012871:Skin Diseases / Q000188:drug therapy*
chemical_list: D000075242:Janus Kinase Inhibitors; D009570:Nitriles; D010880:Piperidines; D011720:Pyrazoles; D011743:Pyrimidines; D011758:Pyrroles; C540383:ruxolitinib; C479163:tofacitinib